The start-up Octogone Medical and Erganeo signed an exclusive license for a non-invasive stroke risk prediction system. A joint innovation by Octogone Medical, Université Paris Cité, INSERM and AP-HP.
Cerebrovascular accident (CVA) is a disease on the rise throughout the world: it is the third leading cause of death and the leading source of non-traumatic motor disability. Carotid plaque rupture has been shown to play a major role in 70% of ischemic strokes - caused by occlusion of an artery in the brain.
With this in mind, the research team led by Prof. Emmanuel Messas (Université Paris Cité, AP-HP - Assistance Publique - Hôpitaux de Paris) and Dr. Frédéric Saldmann has developed a new system for predicting plaque rupture.
The system, designed for people at risk, is based on a medical monitoring device. It is offered in the form of an external patch, equipped with sensors that continuously measure the state of vascular plaques (risk of rupture or vascular plaque detachment) and/or the biomechanical properties of the carotid wall. The data collected is analyzed by artificial intelligence, to predict the risk of stroke non-invasively and in real time.
This momentum was continued with the creation, in October 2020, of the start-up Octogone Medical, co-founded by Emmanuel Messas and Frédéric Saldmann. Three families of patents* were subsequently filed between 2021 and 2023, then extended internationally to Europe, China and the United States.
Erganeo's contribution to valorizing this invention took the form of legal support and an exclusive licensing agreement, signed on April 25, 2025. “Octogone is a promising start-up that will enable the international dissemination of a technology developed by French public research, with a strong medical impact,” explains Naceur Tounekti, President of Erganeo.
This collaboration will allow the start-up to launch the entry into clinical phases in France and Europe in 2025, followed by the marketing phase planned for 2027 in Europe.
Read the press release
*CNRS (Centre National de la Recherche Scientifique), INSERM (Institut National de la Santé et de la Recherche Médicale), AP-HP (Assistance Publique - Hôpitaux de Paris), Université Paris Cité and Octogone Medical
